Vital Proteins for Biomanufacturing Market by Groups, Function, Indication

List of Tables

The Vital Proteins for Biomanufacturing Market is projected to reach USD 94.81 billion by 2030 from USD 48.13 billion in 2022, at a CAGR of 8.84% during the forecast period.

Global Vital Proteins for Biomanufacturing Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 48.13 billion
Estimated Year Value [2023]	USD 52.10 billion
Forecast Year Value [2030]	USD 94.81 billion
CAGR (%)	8.84%

Vital Proteins for Biomanufacturing Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Vital Proteins for Biomanufacturing Market.

Based on Groups, market is studied across Cytokines, Enzymes & Chemicals, Expression Systems, Media & Supplements, Protein A Resins, Quality Control Reagents, and Vectors & Transfection Reagents. The Cytokines is further studied across Chemokines, Colony-stimulating factors, Interferons, Interleukins, and Tumor necrosis factors. The Enzymes & Chemicals is further studied across DNA Capping Enzymes, Endonucleases, Glycosidases, Polyadenylation Enzymes, Protease Inhibitors, and Transcription Enzymes. The Expression Systems is further studied across Bacterial, Insect, Mammalian Cells, and Yeast. The Media & Supplements is further studied across Albumin, Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGFs), Insulin-like Growth Factors (IGFs), Transferrin, and Vascular Endothelial Growth Factor (VEGF). The Expression Systems is projected to witness significant market share during forecast period.

Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines. The Drug Discovery & Development is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Autoimmune Disorders, Infectious Diseases, Oncology, and Rare Genetic Disorders. The Rare Genetic Disorders is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Vital Proteins for Biomanufacturing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Vital Proteins for Biomanufacturing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Vital Proteins for Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., GenScript Biotech Corporation, Johnson & Johnson Services, Inc., Laurus Bio Private Limited, LenioBio GmbH, Lonza Group AG, Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., and Thermo Fisher Scientific Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Vital Proteins for Biomanufacturing Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Vital Proteins for Biomanufacturing Market?

3. What is the competitive strategic window for identifying opportunities in the Vital Proteins for Biomanufacturing Market?

4. What are the latest technology trends and regulatory frameworks in the Vital Proteins for Biomanufacturing Market?

5. What is the market share of the leading vendors in the Vital Proteins for Biomanufacturing Market?

6. Which modes and strategic moves are suitable for entering the Vital Proteins for Biomanufacturing Market?

Product Code: MRR-D47730F51F29

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Vital Proteins for Biomanufacturing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
  - 5.1.1.2. Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
  - 5.1.1.3. Growing interest in personalized medicine necessitates tailored protein therapeutics
- 5.1.2. Restraints
  - 5.1.2.1. High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
- 5.1.3. Opportunities
  - 5.1.3.1. Supportive government policies promoting investments in research & development
  - 5.1.3.2. Ongoing collaborations between academia & industry players for technological innovations in vital proteins
- 5.1.4. Challenges
  - 5.1.4.1. Complexities associated with scaling up production processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Vital Proteins for Biomanufacturing Market, by Groups

6.1. Introduction
6.2. Cytokines
- 6.3.1. Chemokines
- 6.3.2. Colony-stimulating factors
- 6.3.3. Interferons
- 6.3.4. Interleukins
- 6.3.5. Tumor necrosis factors
6.3. Enzymes & Chemicals
- 6.4.1. DNA Capping Enzymes
- 6.4.2. Endonucleases
- 6.4.3. Glycosidases
- 6.4.4. Polyadenylation Enzymes
- 6.4.5. Protease Inhibitors
- 6.4.6. Transcription Enzymes
6.4. Expression Systems
- 6.5.1. Bacterial
- 6.5.2. Insect
- 6.5.3. Mammalian Cells
- 6.5.4. Yeast
6.5. Media & Supplements
- 6.6.1. Albumin
- 6.6.2. Epidermal Growth Factor (EGF)
- 6.6.3. Fibroblast Growth Factors (FGFs)
- 6.6.4. Insulin-like Growth Factors (IGFs)
- 6.6.5. Transferrin
- 6.6.6. Vascular Endothelial Growth Factor (VEGF)
6.6. Protein A Resins
6.7. Quality Control Reagents
6.8. Vectors & Transfection Reagents

7. Vital Proteins for Biomanufacturing Market, by Function

7.1. Introduction
7.2. Diagnostics
7.3. Drug Discovery & Development
- 7.4.1. Biologics
- 7.4.2. Cell & Gene Therapy
- 7.4.3. Vaccines

8. Vital Proteins for Biomanufacturing Market, by Indication

8.1. Introduction
8.2. Autoimmune Disorders
8.3. Infectious Diseases
8.4. Oncology
8.5. Rare Genetic Disorders

9. Americas Vital Proteins for Biomanufacturing Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Vital Proteins for Biomanufacturing Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Vital Proteins for Biomanufacturing Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. Everest Medicines Ltd. acquires rights to 3C-like protease inhibitors to develop antivirals for COVID-19
- 12.3.2. New Product Launch & Enhancement
  - 12.3.2.1. New England Biolabs Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abcam PLC
- 13.1.2. Abnova Corporation
- 13.1.3. Agilent Technologies, Inc.
- 13.1.4. Bio-Rad Laboratories, Inc.
- 13.1.5. BioLegend, Inc. by PerkinElmer, Inc.
- 13.1.6. Biologics International Corporation
- 13.1.7. BPS Bioscience, Inc.
- 13.1.8. Bristol-Myers Squibb Company
- 13.1.9. Creative BioMart Inc.
- 13.1.10. Croyez Bioscience Co., Ltd.
- 13.1.11. Eli Lilly and Company
- 13.1.12. Enzo Life Sciences, Inc.
- 13.1.13. GenScript Biotech Corporation
- 13.1.14. Johnson & Johnson Services, Inc.
- 13.1.15. Laurus Bio Private Limited
- 13.1.16. LenioBio GmbH
- 13.1.17. Lonza Group AG
- 13.1.18. Merck KGaA
- 13.1.19. Meridian Bioscience, Inc. by SD Biosensor Inc.
- 13.1.20. Miltenyi Biotec B.V. & Co. KG
- 13.1.21. Novartis AG
- 13.1.22. ProMab Biotechnologies, Inc.
- 13.1.23. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing